Ulrike I. Attenberger1, Val M. Runge2, Jonathan Williams3, Henrik J. Michaely
1Department of Clinical Radiology and Nuclear Medicine, University Medical Center Manheim, Germany, Mannheim, Baden-Wrttemberg, Germany; 2Scott & White Clinic and Hospital, Texas A&M University Health Science Center, Department of Radiology , Temple, TX, United States; 3Department of Radiology, , Scott & White Clinic and Hospital, Texas A&M University Health Science Center, Temple, TX, United States
Regarding nephrogenic systemic fibrosis (NSF), the injected dose level becomes very important, since NSF is reported to be related to gadolinium chelate injection in patients with an impaired renal function, depending upon chelate stability and dose. With gadobenate dimeglumine, a chelate with transient protein binding and a higher r1 relaxivity became available. Combining a high relaxivity chelate and 3 T offers multiple opportunities for dose reduction without loss in image quality. This was proven in a rat brain glioma model at 1.5 and 3 T, comparing half dose gadobenate dimeglumine vs full dose gadopentetate dimeglumine, a standard extracellular gadolinium chelate.